Treatment of depression in schizophrenia: Systematic review and meta-analysis

British Journal of Psychiatry - Tập 211 Số 4 - Trang 198-204 - 2017
A. G. Gregory1, Pavan Mallikarjun2, Rachel Upthegrove2
1Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham
2Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Forward Thinking Birmingham and School of Psychology, College of Life and Environmental Sciences, University of Birmingham, Birmingham

Tóm tắt

BackgroundDepression in schizophrenia predicts poor outcomes, including suicide, yet the effectiveness of antidepressants for its treatment remains uncertain.AimsTo synthesise the evidence of the effectiveness of antidepressants for the treatment of depression in schizophrenia.MethodMultiple databases Were searched and inclusion Criteria included participants aged over 18 years with schizophrenia or related psychosis with a depressive episode. Papers were quality assessed used the Cochrane risk bias tool. Meta-analyses were performed for risk difference and standardised mean difference of all antidepressants, antidepressant class and individual antidepressant where sufficient studies allowed.ResultsA total of 26 moderate- to low-quality trials met inclusion criteria. In meta-analysis a significant risk difference was found in favour of antidepressant treatment, with a number needed to treat of 5 (95% CI 4–9). Studies using tools specifically designed to assess depression in schizophrenia showed a larger effect size. However, after sensitivity analysis standardised mean difference of all antidepressants did not show a statistically significant improvement in depression score at end-point, neither did any individual antidepressant class.ConclusionsAntidepressants may be effective for the treatment of depression in schizophrenia, however, the evidence is mixed and conclusions must be qualified by the small number of low- or moderate-quality studies. Further sufficiently powered, high-quality studies are needed.

Từ khóa


Tài liệu tham khảo

10.1002/hup.1017

10.1093/schbul/sbn135

Singh, 1978, A controlled clinical study of trazodone in chronic schizophrenic patients with pronounced depressive symptomatology, Curr Ther Res, 23, 485

10.1097/YCO.0b013e32835d9efb

10.1001/archpsyc.64.10.1123

Whitehead, 2002, Antidepressants for people with both schizophrenia and depression, Cochrane Database Syst Rev, 2, CD002305

10.1016/j.schres.2006.09.027

Upthegrove, 2016, Antidepressant treatment of depression in schizophrenia: a systematic review and meta-analysis

Upthegrove, 2017, Depression and schizophrenia: cause, consequence or trans-diagnostic issue?, Schizophr Bull, 43

Terevnikov, 2011, Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase, Hum Psychopharmacol, 26, 10.1002/hup.1189

10.1016/j.schres.2016.02.034

10.1016/S0920-9964(99)00197-8

10.1034/j.1600-0447.2003.00132.x

10.1001/archpsyc.1995.03950130029004

Heifer, 2017, Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis, Am J Psychiatry, 173

10.4088/JCP.08m04261

10.1192/bjp.139.2.89

Mico, 2011, Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial, Int Clin Psychopharmacol, 26

Izakova L , Andre I , Halaris A . Combination therapy or monotherapy for the depressed type of schizoaffective disorder. Neuropsychiatr Dis Treat 2009; 91–101.

10.1016/j.schres.2005.01.004

10.1111/j.1600-0447.1997.tb09925.x

Higgins, 2011, Cochrane Handbook for Systematic Reviews of Interventions.

10.1001/archpsyc.1979.01780050079010

1994, Diagnostic and Statistical Manual of Mental Disorder

Omranifard, 2012, Sertraline as an add-on treatment for depressive symptoms in stable schizophrenia: a double-blind randomized controlled trial, J Res Med Sci, 17, S1

10.1001/archpsyc.1978.01770300115013

10.1097/00004850-199701000-00004

2014, Psychosis and Schizophrenia in Adults: Treatment and Management.

10.1192/bjp.bp.114.155945

10.1001/archgenpsychiatry.2011.1532

10.1002/gps.508

10.1016/0920-9964(95)00107-7

10.1097/JCP.0b013e3182664cfc

10.1016/j.psychres.2014.03.023

Chavda, 2011, Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression, J Pharmacol Pharmacother, 2, 10.4103/0976-500X.77091

10.1177/0269881103017001713

Arroll, 2009, Antidepressants versus placebo for depression in primary care, Cochrane Database Syst Rev, 3, cd007954

10.1097/00004714-200202000-00004

10.1192/bjp.bp.112.116285

2011, Citalopram and escitalopram: QT interval prolongation

10.1097/NMD.0b013e31825bfa1d

Upthegrove, 2010, The evolution of depression and suicidality in first episode psychosis, Acta Psychiatr Scand, 122, 10.1111/j.1600-0447.2009.01506.x

10.1016/j.jad.2013.01.018

10.1097/00004850-200103000-00003

10.1177/0269881107086283

10.1177/0269881110391123

10.1002/j.1552-4604.1981.tb01730.x

10.1097/JCP.0b013e3182971e68

10.1016/j.cpr.2016.03.004

1992, The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines.

2015, Guidance to Support the Introduction of Access and waiting Time Standards for Mental Health Services in 2015/16.

10.1016/S0920-9964(00)00135-3

Thông tin
Thông tin xuất bản

British Journal of Psychiatry

Tập 211 Số 4

198-204

Thông tin tác giả